You bend further than everyone else in the room, and you have been hurting for years. A shoulder that slides. Someone called you double-jointed, someone else suggested fibromyalgia, and more than one person told you your imaging looked fine. Each provider treated the joint in front of them. Nobody treated the pattern.
Two review papers published in 2026 — one in pain medicine, one in gastroenterology — reached strikingly similar conclusions from opposite ends of the body. In people with hypermobility, the problem is usually not that no options exist. It is that the evaluation, and the order it happens in, gets skipped.
Most people wait almost two decades for the word hypermobility
In February 2026, BMC Medicine published a study of 1,754 adults with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorders (HSD), recruited online through a UK support organization. The average time from first symptoms to a diagnosis was 18.85 years (SD 12.08). For respondents who were not autistic, the wait was longest — a mean of 19.40 years.
What makes that number sting is the other thing the study found: Beighton scores, the flexibility measure clinicians use, were essentially the same across every group it compared (means of 6.49, 6.40 and 6.11). The hypermobility was equally findable in all of them. What differed was whether anyone looked. Participants were self-selected through a condition-specific support community and were predominantly white and largely female, so the 19-year figure describes a delay that clearly happens — not how long it happens to everybody.
Hypermobility pain is not one problem. It is at least four
In July 2026, Current Pain and Headache Reports published a review of pain management in Ehlers-Danlos syndrome. Its central observation is the most useful sentence a hypermobile patient can read: pain in EDS is typically multifaceted, involving musculoskeletal, neuropathic, autonomic and centralized components.
The review names specific sources feeding those components — joint instability, repetitive microtrauma, small fiber neuropathy, and dysfunctional central pain processing — and adds that there is growing evidence nociceptive mechanisms and psychological factors contribute as well. An unstable joint and a sensitized nervous system are not the same problem, are not measured the same way, and do not respond to the same intervention.
That is also why the advice you found online contradicts itself. A strengthening program is transformative for the person whose dominant problem is joint instability and close to useless for the person whose dominant problem is central pain processing, so two people can describe opposite experiences of one treatment and both be telling the truth.
A second 2026 review reached the same conclusion about the gut
In August 2026, Current Gastroenterology Reports reviewed gastrointestinal symptoms and nutrition support across hEDS/HSD, postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS). GI symptoms, it reports, are common and often severe across these overlapping conditions, clinical practice remains variable, and escalation to non-oral nutrition support may occur prematurely.
The specifics are worth stating plainly. Emerging data point to a high prevalence of disorders of gut-brain interaction, avoidant/restrictive food intake disorder and malnutrition in this population, and enteral and parenteral nutrition are frequently started without adequate trials of conservative and behavioral interventions — after which de-escalation remains difficult. The authors recommend a coordinated evaluation using validated tools before escalation, with enteral nutrition preferred when oral strategies fail and parenteral nutrition reserved for intestinal failure.
Venturis Clinic does not provide enteral or parenteral nutrition. That review is here because two specialties, looking at two organ systems in the same patients, independently concluded that the failure point is sequence — which is also why your hypermobility and your reflux belong in one conversation. More on that overlap: why MCAS, POTS and EDS travel together.
What actually changes once hypermobility is written down
A short clinical commentary in the Journal of Back and Musculoskeletal Rehabilitation, published early in 2026, makes the practical case — and being three pages rather than a systematic review, it should be weighed accordingly. Detection, the author argues, can be easy: primarily observation of flexibility in the thumb, finger, elbow and knee. The diagnosis is missed commonly enough that he recommends clinicians spend a month performing those maneuvers on every chronic pain patient, simply to build the habit of looking.
The label changes the plan. As the commentary puts it, stretching an injured tendon or ligament is a common approach in other patients, and in this population those approaches are often to be avoided. It also lists conditions worth asking about once hypermobility is identified — POTS, mast cell activation syndrome, small fiber neuropathy, migraine and Chiari malformation — along with reported increases in risk of autism spectrum disorder (7.4-fold), ADHD (5.6-fold) and depression (3.4-fold).
The underlying point survives the weighing: a five-second observation changes which questions get asked and which treatments get avoided.
What the 2026 research does not show
The pain review is explicit, and we are not going to soften it: high-quality evidence supporting interventional and specific pharmacologic regimens in EDS remains sparse. It notes that complementary approaches including trigger-point injections have been investigated and may provide benefit, while the overall evidence base stays thin.
That includes injection-based approaches generally. Venturis offers prolotherapy, PRP therapy and ozone-based therapies, and none of them is FDA-approved for hypermobility-related pain. No published evidence supports telling you that a series of injections resolves a connective tissue disorder, and we will not tell you that. What the 2026 reviews point to instead is integrated care — rehabilitation aimed at joint stabilization and neuromuscular control, symptom-specific medication, and behavioral support — with an individualized, mechanism-informed approach on top. Results vary, and any procedure is a component of a plan rather than the plan.
Where a clinic like ours fits in Oklahoma City
Dr. Alvin Philipose has practiced regenerative and functional medicine for over 25 years, and Venturis Clinic is one of a small number of Oklahoma practices that works with Ehlers-Danlos syndrome, POTS and MCAS as a connected picture rather than three unrelated referrals — which is what the conditions we support reflect. The orthostatic side of that picture is described on our POTS integrative treatment page. We are not a genetics, gastroenterology or neurology practice, and some patients are better served by a referral than by anything we offer.
Who is generally not a good candidate
Candidates are typically evaluated for several things that would change or delay a regenerative or infusion-based plan. This is a starting point rather than a complete list, and scope is decided during a consultation:
- Active infection, particularly at or near a planned injection site
- Bleeding or platelet disorders, or significant anemia
- Active cancer treatment, where supportive therapy belongs in a conversation with your oncology team first
- Pregnancy
- Unexplained weight loss, bleeding, vomiting or difficulty swallowing — these need a gastroenterology workup first, not a wellness plan alongside
- Needing a definitive answer or meaningful relief within the next few weeks
- Looking for a single procedure to resolve a connective tissue disorder, or primarily needing a formal genetic diagnosis
Four questions worth asking any clinic
- Will you score my hypermobility and record the number, so the next provider does not start over?
- Which component of my pain is this treatment aimed at — joint, nerve, autonomic or central sensitization?
- What conservative options should I try first, and for how long, before escalating?
- Who do you refer to for the parts you do not handle?
Frequently asked questions
What is the difference between hEDS and hypermobility spectrum disorder?
Both describe symptomatic joint hypermobility. Hypermobile Ehlers-Danlos syndrome is diagnosed when a person meets a formal published checklist of features; hypermobility spectrum disorder describes symptomatic hypermobility that does not meet that checklist. The 2026 research discussed here generally studies the two groups together, because symptom burden and management questions overlap heavily.
Is stretching bad for me if I am hypermobile?
This is a question for the clinician managing your rehabilitation, not for an article. What the 2026 commentary states is that stretching an injured tendon or ligament, a common approach in other patients, is often to be avoided in this population, and the 2026 pain review emphasizes physical therapy aimed at joint stabilization and neuromuscular control instead. The distinction between stabilizing and lengthening is worth raising at your next appointment.
Can injections help hypermobility pain?
The honest answer from the 2026 pain review is that high-quality evidence supporting interventional regimens in EDS remains sparse, though it notes trigger-point injections and other complementary approaches have been investigated and may provide benefit. Prolotherapy, PRP and ozone therapies are not FDA-approved for hypermobility-related pain. Some patients explore them as one component of a broader plan. Results vary, and no outcome is guaranteed.
Why do my stomach problems and my joint pain seem related?
A 2026 Current Gastroenterology Reports review found that gastrointestinal symptoms are common and often severe across hEDS/HSD, POTS and MCAS, and that disorders of gut-brain interaction, restrictive eating patterns and malnutrition are prevalent in this group. Its main warning is that nutrition support often gets escalated before conservative options have had a real trial. The connection is recognized; what it means for one person still requires evaluation.
Does hypermobility explain why my heart races when I stand up?
Orthostatic intolerance and POTS are among the conditions the 2026 commentary lists as worth asking about once hypermobility is identified, but that association does not diagnose anyone. A racing heart on standing has several possible explanations and is evaluated with history, vitals and appropriate testing during a consultation, not from a symptom list.
What should I bring to a first appointment in Oklahoma City?
Bring imaging reports, prior specialist letters, a list of every medication and supplement, and — most usefully — a short written timeline of which joints have caused problems and when. If anyone has ever scored your hypermobility, bring that number. Patients may experience that appointment as the first time the whole pattern was looked at in one sitting.
Talking with someone about the whole pattern
The goal of a first conversation is not to sell you a procedure. It is to sort out which parts of the picture are joint, which are nerve, which are autonomic, and which belong to someone else. Venturis Clinic offers a free 15-minute phone consultation — you are welcome to use it to ask the four questions above before booking anything.
Venturis Clinic
7917 N May Ave, Suite B
Oklahoma City, OK 73120
(405) 848-7246
This content is for educational purposes only and is not medical advice, diagnosis, or treatment. Individual results vary and no outcome is guaranteed. Venturis Clinic offers regenerative, functional, and alternative medicine services; some therapies discussed are not FDA-approved for the uses described. Talk with a qualified healthcare provider about your specific situation before beginning any treatment.
Sources
- Banerjee RC, Ramsey ME, Buras BE, Potharaju P, Shekoohi S, Abd-Elsayed A, Kaye AD. Emerging Clinical Concepts in Pain Management of Ehlers–Danlos Syndrome. Current Pain and Headache Reports. 2026;30(1):92. Published 22 July 2026. DOI: 10.1007/s11916-026-01532-1
- Katz J, Angeli AM, Alicea A, Austin K. Gastrointestinal Manifestations and Nutrition Support in Hypermobile Ehlers-Danlos, Postural Orthostatic Tachycardia, and Mast Cell Activation Syndromes. Current Gastroenterology Reports. 2026;28(1):26. Published 18 August 2026. DOI: 10.1007/s11894-026-01050-5
- Crompton CJ, Efthimiou TN, Dockrell DM, Berg KM. Health experiences and outcomes of autistic and non-autistic adults with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder. BMC Medicine. 2026;24(1):193. Published 25 February 2026. DOI: 10.1186/s12916-026-04713-2
- Haig AJ. Bend the fingers: Ehlers Danlos syndrome and the associated disorders that impact treatment of chronic musculoskeletal pain. Journal of Back and Musculoskeletal Rehabilitation. 2026;39(2):372–374. DOI: 10.1177/10538127261422915
